Format

Send to

Choose Destination
Sci Rep. 2019 Dec 18;9(1):19336. doi: 10.1038/s41598-019-55875-4.

A de novo EGR2 variant, c.1232A > G p.Asp411Gly, causes severe early-onset Charcot-Marie-Tooth Neuropathy Type 3 (Dejerine-Sottas Neuropathy).

Author information

1
Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, NSW, Australia. bgro4046@uni.sydney.edu.au.
2
Sydney Medical School, University of Sydney, Sydney, NSW, Australia. bgro4046@uni.sydney.edu.au.
3
Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA.
4
Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, NSW, Australia.
5
Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
6
Molecular Medicine Laboratory, Concord Repatriation General Hospital, Concord, NSW, Australia.
7
Department of Neurology, Concord Repatriation General Hospital, Concord, NSW, Australia.
8
Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
9
Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, NSW, Australia. marina.kennerson@sydney.edu.au.
10
Sydney Medical School, University of Sydney, Sydney, NSW, Australia. marina.kennerson@sydney.edu.au.
11
Molecular Medicine Laboratory, Concord Repatriation General Hospital, Concord, NSW, Australia. marina.kennerson@sydney.edu.au.

Abstract

EGR2 (early growth response 2) is a crucial transcription factor for the myelination of the peripheral nervous system. Mutations in EGR2 are reported to cause a heterogenous spectrum of peripheral neuropathy with wide variation in both severity and age of onset, including demyelinating and axonal forms of Charcot-Marie Tooth (CMT) neuropathy, Dejerine-Sottas neuropathy (DSN/CMT3), and congenital hypomyelinating neuropathy (CHN/CMT4E). Here we report a sporadic de novo EGR2 variant, c.1232A > G (NM_000399.5), causing a missense p.Asp411Gly substitution and discovered through whole-exome sequencing (WES) of the proband. The resultant phenotype is severe demyelinating DSN with onset at two years of age, confirmed through nerve biopsy and electrophysiological examination. In silico analyses showed that the Asp411 residue is evolutionarily conserved, and the p.Asp411Gly variant was predicted to be deleterious by multiple in silico analyses. A luciferase-based reporter assay confirmed the reduced ability of p.Asp411Gly EGR2 to activate a PMP22 (peripheral myelin protein 22) enhancer element compared to wild-type EGR2. This study adds further support to the heterogeneity of EGR2-related peripheral neuropathies and provides strong functional evidence for the pathogenicity of the p.Asp411Gly EGR2 variant.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center